![](/cdn/assets/images/search/clock.png)
We could not find any results for:
Make sure your spelling is correct or try broadening your search.
Share Name | Share Symbol | Market | Type | Share ISIN | Share Description |
---|---|---|---|---|---|
Celadon Pharmaceuticals Plc | LSE:CEL | London | Ordinary Share | GB00BDQYGP38 | ORD 1P |
Price Change | % Change | Share Price | Bid Price | Offer Price | High Price | Low Price | Open Price | Shares Traded | Last Trade | |
---|---|---|---|---|---|---|---|---|---|---|
1.50 | 2.52% | 61.00 | 57.00 | 65.00 | 61.00 | 59.50 | 59.50 | 12,246 | 14:00:11 |
Industry Sector | Turnover | Profit | EPS - Basic | PE Ratio | Market Cap |
---|---|---|---|---|---|
Investment Advice | 149k | -7.14M | -0.1082 | -5.64 | 39.26M |
RNS Number:7815R Celsis International PLC 2 October 2000 CELSIS INTERNATIONAL PLC Announces Supply Agreement with Medical Packaging Corporation ("MPC") Celsis International plc, the microbial risk management group, today announces a Supply Agreement with Medical Packaging Corporation ("MPC") for the new Celsis snapshot device. Medical Packaging Corporation, based in the United States, is a leading manufacturer of medical devices for the diagnostic and clinical laboratory industries. MPC will supply snapshot, Celsis' new innovative hygiene monitoring device, from its base in California. Snapshot, due to be launched in early October, is the world's first hygiene test to contain liquid stable bioluminescence reagent. This novel reagent developed by Celsis scientists in Cambridge is a major step forward in reagent technology and gives improved performance, consistency as well as simplifying the manufacturing processes. The new device will provide users with improved confidence in hygiene monitoring results, through more precise and reliable testing in an easy-to-use format. MPC will also work with Celsis on a program of continuous improvement to make more user friendly and competitive sampling devices. Peter Grant, Director of Business Development, Celsis, said: "We are extremely pleased to be entering in to a supply agreement with MPC for the snapshot device, and are very optimistic about our future plans together. The combination of Celsis' technology and MPC's manufacturing facilities will enhance our product offering. Together with the relaunch of systemSURE last year, this reinforces Celsis' strategy to grow our presence in the hygiene monitoring sector." Enquiries: Celsis International plc Peter Grant, Director of Business Development +44 (0) 1223 426 008 Jenny Parsons, Corporate Communications Brunswick Group Melissa Miller +44 (0) 207 404 5959 Notes to Editors: Celsis International plc Celsis International plc specialises in the development and supply of rapid diagnostic and monitoring systems to detect and measure microbial contamination. It has successfully developed a range of tests for use in the food, beverage, pharmaceutical, cosmetic and toiletries industries. These tests are based upon the technology of ATP Bioluminescence; such tests detect the presence of microbial contamination by monitoring light emitted when adenosine triphosphate ("ATP"), a naturally occurring substance present in all living organisms, is brought into contact with luciferase, an enzyme produced by fireflies. Medical Packaging Corporation MPC is both a contract and an original manufacturer of medical devices for the in vitro diagnostic and clinical laboratory industries, located in Camarillo, California. Their primary capabilities include product design and development expertise and automated manufacture.
1 Year Celadon Pharmaceuticals Chart |
1 Month Celadon Pharmaceuticals Chart |
It looks like you are not logged in. Click the button below to log in and keep track of your recent history.
Support: +44 (0) 203 8794 460 | support@advfn.com
By accessing the services available at ADVFN you are agreeing to be bound by ADVFN's Terms & Conditions